185 related articles for article (PubMed ID: 36419394)
1. [Predictive Value of LIPI and iSEND Immune Scoring System
in Immunotherapy of Advanced Non-small Cell Lung Cancer].
Luo Y; Wang X; Wang Y; Zhang G
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):803-810. PubMed ID: 36419394
[TBL] [Abstract][Full Text] [Related]
2. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
[TBL] [Abstract][Full Text] [Related]
3. [Effect of dNLR and LIPI scores on the prognosis of elderly patients with non-surgical treatment of non-small cell lung cancer].
Xie JH; Liu MM; Sun NN; Zhang L; Zhang HZ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):975-980. PubMed ID: 36164700
[No Abstract] [Full Text] [Related]
4. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
6. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
[TBL] [Abstract][Full Text] [Related]
7. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
[TBL] [Abstract][Full Text] [Related]
8. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
[TBL] [Abstract][Full Text] [Related]
10. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
[TBL] [Abstract][Full Text] [Related]
11. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract][Full Text] [Related]
13. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.
Zhang T; Xue W; Wang D; Xu K; Wu L; Wu Y; Zhou Z; Chen D; Feng Q; Liang J; Xiao Z; Hui Z; Lv J; Wang X; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Radiother Oncol; 2021 Mar; 156():244-250. PubMed ID: 33418003
[TBL] [Abstract][Full Text] [Related]
14. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
Xiong A; Xu J; Wang S; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Nie W; Zhong H; Zhang X
Front Immunol; 2023; 14():1173025. PubMed ID: 37304273
[TBL] [Abstract][Full Text] [Related]
15. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
16. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.
Pan Y; Si H; Jia R; Deng G; Yan H; Fan M; Gou M; Chen S; Zhang N; Shi Y; Qian N; Dai G
J Oncol; 2022; 2022():1427779. PubMed ID: 35342416
[TBL] [Abstract][Full Text] [Related]
17. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
19. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
